{"id":40096,"date":"2026-10-21T10:17:50","date_gmt":"2026-10-21T08:17:50","guid":{"rendered":"https:\/\/ggba.swiss\/?p=40096"},"modified":"2026-10-21T10:17:54","modified_gmt":"2026-10-21T08:17:54","slug":"orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/","title":{"rendered":"Orbis Medicines and Novo Nordisk partner in a deal worth up to USD 1.4 billion"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.orbismedicines.com\/\">Orbis Medicines<\/a> has entered a strategic collaboration and license agreement with <a href=\"https:\/\/www.novonordisk.com\/\">Novo Nordisk<\/a> to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. Announced on September 17, 2026, the deal is worth up to USD 1.4 billion, covering an upfront payment and potential development and commercial milestones, with tiered royalties on future product sales. Novo Nordisk will also make a strategic investment in Orbis. The amounts of the upfront payment, royalties and investment were not disclosed, and the targets were not named.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">An AI-driven platform for oral alternatives to injectables<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Orbis focuses on macrocycles, which it calls nCycles: orally bioavailable molecules aimed at targets already validated by injectable biologic drugs. They are designed with its nGen platform, which combines generative AI, high-throughput synthesis and a multi-parameter optimization engine in a &#8220;lab in a loop.&#8221; According to the company, nGen draws on hit-finding libraries of 100 billion compounds and can synthesize and analyze up to 100,000 macrocycles in weeks.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Morten Graugaard, CEO of Orbis Medicines, says the future of oral biologic drug discovery &#8220;lies at the intersection of AI&#8221; with proprietary macrocycle datasets and automated chemistry. Brian Vandahl, Senior Vice President, Therapeutics Discovery at Novo Nordisk, says the collaboration could &#8220;unlock innovative oral treatment options for patients with cardiometabolic diseases.&#8221;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Scientific roots at EPFL<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The science behind Orbis was developed at <a href=\"https:\/\/www.epfl.ch\/en\/\">EPFL<\/a> by Professor Christian Heinis and Sevan Habeshian. <a href=\"https:\/\/novoholdings.com\/\">Novo Holdings<\/a> officially founded the company in 2021 and launched it publicly in February 2024 with a EUR 26 million seed round co-led with <a href=\"https:\/\/www.forbion.com\/\">Forbion<\/a>. A EUR 90 million Series A led by <a href=\"https:\/\/www.nea.com\/\">NEA<\/a> followed in January 2025, with Lilly Ventures, Cormorant and EIFO joining as new investors. Orbis has raised EUR 116 million in venture funding to date.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orbis Medicines, a drug discovery company with operations in Lausanne and Copenhagen, has entered a multi-target collaboration with Novo Nordisk worth up to USD 1.4 billion to develop oral macrocycle drugs for cardiometabolic diseases.<\/p>\n","protected":false},"author":6,"featured_media":40097,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[893,894,890,886],"class_list":["post-40096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-artificial-intelligence","tag-financing","tag-healthcare","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk<\/title>\n<meta name=\"description\" content=\"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk\" \/>\n<meta property=\"og:description\" content=\"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T08:17:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-21T08:17:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Orbis Medicines and Novo Nordisk partner in a deal worth up to USD 1.4 billion\",\"datePublished\":\"2026-10-21T08:17:50+00:00\",\"dateModified\":\"2026-10-21T08:17:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Financing\",\"Healthcare\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\",\"url\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\",\"name\":\"Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"datePublished\":\"2026-10-21T08:17:50+00:00\",\"dateModified\":\"2026-10-21T08:17:54+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Orbis Medicines develops oral macrocycle drugs with its AI-driven nGen platform. | \u00a9 Orbid Medicines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orbis Medicines and Novo Nordisk partner in a deal worth up to USD 1.4 billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk","description":"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/","og_locale":"en_US","og_type":"article","og_title":"Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk","og_description":"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.","og_url":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-10-21T08:17:50+00:00","article_modified_time":"2026-10-21T08:17:54+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Orbis Medicines and Novo Nordisk partner in a deal worth up to USD 1.4 billion","datePublished":"2026-10-21T08:17:50+00:00","dateModified":"2026-10-21T08:17:54+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/"},"wordCount":291,"image":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","keywords":["Artificial Intelligence","Financing","Healthcare","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/","url":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/","name":"Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","datePublished":"2026-10-21T08:17:50+00:00","dateModified":"2026-10-21T08:17:54+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Orbis Medicines, which also operates in Lausanne, has entered a collaboration worth up to USD 1.4 billion with Novo Nordisk on oral drugs.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","width":1180,"height":811,"caption":"Orbis Medicines develops oral macrocycle drugs with its AI-driven nGen platform. | \u00a9 Orbid Medicines"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Orbis Medicines and Novo Nordisk partner in a deal worth up to USD 1.4 billion"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=40096"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40096\/revisions"}],"predecessor-version":[{"id":40100,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/40096\/revisions\/40100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/40097"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=40096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=40096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=40096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}